S&P 500 Futures
(0.64%) 5 362.00 points
Dow Jones Futures
(0.16%) 39 846 points
Nasdaq Futures
(1.12%) 18 996 points
Oil
(1.26%) $78.55
Gas
(1.48%) $2.88
Gold
(-0.91%) $2 371.10
Silver
(-1.53%) $31.02
Platinum
(0.21%) $1 051.90
USD/EUR
(-0.31%) $0.921
USD/NOK
(-0.87%) $10.60
USD/GBP
(-0.17%) $0.785
USD/RUB
(0.29%) $90.45

Realtime updates for Mesoblast Limited [MESO]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Upcoming Earnings Alert

Quarter results today
(bmo 2024-05-23)

Expected move: +/- 5.50%

Last Updated22 May 2024 @ 16:00

-0.25% $ 7.89

Live Chart Being Loaded With Signals

Commentary (22 May 2024 @ 16:00):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland...

Stats
Today's Volume 236 612
Average Volume 2.31M
Market Cap 859.59M
EPS $0 ( 2024-03-25 )
Next earnings date ( $-0.320 ) 2024-07-29
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -8.31
ATR14 $0.0240 (0.30%)

Volume Correlation

Long: -0.26 (neutral)
Short: 0.60 (weak)
Signal:(50.435) Neutral

Mesoblast Limited Correlation

10 Most Positive Correlations
NN0.959
LABP0.95
GERN0.941
QRHC0.935
PESI0.93
VCTR0.93
IVCB0.93
KALU0.928
CENX0.926
WIRE0.926
10 Most Negative Correlations
EZGO-0.935
LUNA-0.934
CABA-0.933
ISSC-0.931
ATNF-0.927
AZ-0.923
RCMT-0.923
CMTL-0.92
MBIO-0.92
APDN-0.919

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mesoblast Limited Correlation - Currency/Commodity

The country flag 0.15
( neutral )
The country flag -0.13
( neutral )
The country flag 0.00
( neutral )
The country flag -0.26
( neutral )
The country flag -0.16
( neutral )
The country flag -0.64
( weak negative )

Mesoblast Limited Financials

Annual 2023
Revenue: $7.50M
Gross Profit: $-20.23M (-269.72 %)
EPS: $-1.050
FY 2023
Revenue: $7.50M
Gross Profit: $-20.23M (-269.72 %)
EPS: $-1.050
FY 2022
Revenue: $10.21M
Gross Profit: $-20.55M (-201.21 %)
EPS: $-1.330
FY 2021
Revenue: $7.46M
Gross Profit: $0.00 (0.00 %)
EPS: $-0.817

Financial Reports:

No articles found.

Mesoblast Limited Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Mesoblast Limited

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators